CBX5 and central nervous system cancer: It has been reported that CBX5 and H3K9me3 are enriched in the FAS and PUMA promoters in glioma, indicating that CBX5 could suppress apoptotic activators by sustaining the methylation level of H3K9me3 (Lai et al., 2017).